Northeast Pharmaceutical Group Co Ltd Cash Flow-to-Debt Ratio
Northeast Pharmaceutical Group Co Ltd cash flow-to-debt ratio. Northeast Pharmaceutical Group Co Ltd (000597) has a Cash Flow-to-Debt Ratio of 0.03x as of September 2025, meaning its operating cash flow of CN¥274.09 Million could theoretically repay 0% of its total liabilities (CN¥8.05 Billion) in one year. Check Northeast Pharmaceutical Group Co Ltd cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Northeast Pharmaceutical Group Co Ltd (1998–2025)
Cash flow-to-debt ratio of Northeast Pharmaceutical Group Co Ltd from 1998 to 2025. Historical debt coverage capacity for Northeast Pharmaceutical Group Co Ltd across 28 annual periods. Check cash flow reinvestment rate of Northeast Pharmaceutical Group Co Ltd to assess the company's total reinvestment commitment from operating cash flow.
Northeast Pharmaceutical Group Co Ltd Cash Flow-to-Debt Ratio by Year (1998–2025)
Northeast Pharmaceutical Group Co Ltd cash flow-to-debt ratio by year from 1998 to 2025. Year-by-year debt coverage analysis for Northeast Pharmaceutical Group Co Ltd. For the full cash flow conversion analysis, see 000597 cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.15x | CN¥1.11 Billion | CN¥7.22 Billion | ▲ +79.3% |
| 2024 | 0.09x | CN¥758.76 Million | CN¥8.88 Billion | ▲ +47.4% |
| 2023 | 0.06x | CN¥586.75 Million | CN¥10.11 Billion | ▼ -52.4% |
| 2022 | 0.12x | CN¥1.11 Billion | CN¥9.10 Billion | ▲ +45.1% |
| 2021 | 0.08x | CN¥746.51 Million | CN¥8.89 Billion | ▲ +18.3% |
| 2020 | 0.07x | CN¥570.92 Million | CN¥8.04 Billion | ▲ +73.6% |
| 2019 | 0.04x | CN¥352.60 Million | CN¥8.62 Billion | ▲ +16.6% |
| 2018 | 0.04x | CN¥285.09 Million | CN¥8.13 Billion | ▲ +193.7% |
| 2017 | -0.04x | CN¥-301.20 Million | CN¥8.05 Billion | ▼ -171.6% |
| 2016 | 0.05x | CN¥384.51 Million | CN¥7.36 Billion | ▲ +229.9% |
| 2015 | 0.02x | CN¥99.70 Million | CN¥6.29 Billion | ▲ +96.0% |
| 2014 | 0.01x | CN¥46.99 Million | CN¥5.81 Billion | ▲ +118.1% |
| 2013 | -0.04x | CN¥-266.38 Million | CN¥5.96 Billion | ▼ -320.4% |
| 2012 | 0.02x | CN¥86.09 Million | CN¥4.24 Billion | ▲ +135.9% |
| 2011 | -0.06x | CN¥-233.32 Million | CN¥4.13 Billion | ▼ -178.1% |
| 2010 | 0.07x | CN¥255.96 Million | CN¥3.54 Billion | ▼ -52.7% |
| 2009 | 0.15x | CN¥615.91 Million | CN¥4.03 Billion | ▼ -45.4% |
| 2008 | 0.28x | CN¥709.03 Million | CN¥2.53 Billion | ▲ +205.2% |
| 2007 | 0.09x | CN¥198.56 Million | CN¥2.16 Billion | ▲ +210.9% |
| 2006 | -0.08x | CN¥-106.00 Million | CN¥1.28 Billion | ▼ -203.9% |
| 2005 | 0.08x | CN¥111.40 Million | CN¥1.40 Billion | ▼ -41.5% |
| 2004 | 0.14x | CN¥211.06 Million | CN¥1.55 Billion | ▼ -2.3% |
| 2003 | 0.14x | CN¥230.08 Million | CN¥1.65 Billion | ▲ +60.0% |
| 2002 | 0.09x | CN¥157.41 Million | CN¥1.81 Billion | ▲ +106.8% |
| 2001 | 0.04x | CN¥78.84 Million | CN¥1.87 Billion | ▲ +105.6% |
| 2000 | 0.02x | CN¥36.13 Million | CN¥1.76 Billion | ▼ -35.1% |
| 1999 | 0.03x | CN¥54.62 Million | CN¥1.73 Billion | ▲ +760.8% |
| 1998 | 0.00x | CN¥-7.59 Million | CN¥1.59 Billion | — |